SpringWorks Therapeutics
SWTX
SWTX was delisted on the 30th of June, 2025.
148 hedge funds and large institutions have $1.64B invested in SpringWorks Therapeutics in 2022 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 56 increasing their positions, 44 reducing their positions, and 19 closing their positions.
939% more call options, than puts
Call options by funds: $20.8M | Put options by funds: $2.01M
75% more funds holding in top 10
Funds holding in top 10: 4 → 7 (+3)
35% more capital invested
Capital invested by funds: $1.21B → $1.64B (+$428M)
32% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 19
27% more repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 44
3% more funds holding
Funds holding: 143 → 148 (+5)
10.49% less ownership
Funds ownership: 111.87% → 101.38% (-10%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$99.2M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$67.9M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$55.9M |
| 4 |
BC
Boxer Capital
San Diego,
California
|
+$38.6M |
| 5 |
AG
Artal Group
Luxembourg
|
+$33.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$25.6M |
| 2 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$21.4M |
| 3 |
State Street
Boston,
Massachusetts
|
-$16.2M |
| 4 |
O
OrbiMed
New York
|
-$14.4M |
| 5 |
Nomura Holdings
Tokyo,
Japan
|
-$13.4M |
SWTX Hedge Fund Activity: Q3 2022 in Review
148 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in SpringWorks Therapeutics (SWTX) for Q3 2022, worth a combined $1.64B — up 35% from $1.21B a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new SWTX positions and 19 closed out — a net gain of 6 holders — while 56 added to existing stakes and 44 trimmed.
The largest buyer was EcoR1 Capital, opening a new position worth an estimated $99.2M. The largest seller was Driehaus Capital Management, cutting an estimated $25.6M.
- 148 institutional investors held SpringWorks Therapeutics (SWTX) as of Q3 2022, up from 143 in Q2 2022.
- Funds reported $1.64B of SpringWorks Therapeutics stock for Q3 2022, up 35% quarter-over-quarter.
- 25 funds opened new SpringWorks Therapeutics positions in Q3 2022 and 19 closed out, a net change of +6 holders.
- The largest SpringWorks Therapeutics buyer in Q3 2022 was EcoR1 Capital, an estimated $99.2M added.
- The largest SpringWorks Therapeutics seller in Q3 2022 was Driehaus Capital Management, an estimated $25.6M sold.
Based on aggregated 13F filings for Q3 2022.